ALBERT LABS INTL. CORP. (F:VB50) — Market Cap & Net Worth
Market Cap & Net Worth: ALBERT LABS INTL. CORP. (VB50)
ALBERT LABS INTL. CORP. (F:VB50) has a market capitalization of $372.07K (€318.25K) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #31152 globally and #2754 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALBERT LABS INTL. CORP.'s stock price €0.01 by its total outstanding shares 74413267 (74.41 Million). Also see VB50 total asset value for a full breakdown of the balance sheet.
ALBERT LABS INTL. CORP. Market Cap History: 2022 to 2026
ALBERT LABS INTL. CORP.'s market capitalization history from 2022 to 2026. Data shows change from $2.00 Million to $434.98K (-49.39% CAGR). Also see cash efficiency ratio of ALBERT LABS INTL. CORP. for how efficiently the company converts equity into cash flow.
ALBERT LABS INTL. CORP. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALBERT LABS INTL. CORP.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of ALBERT LABS INTL. CORP. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VB50 by Market Capitalization
Companies near ALBERT LABS INTL. CORP. in the global market cap rankings as of September 19, 2026. Explore VB50 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Key companies related to ALBERT LABS INTL. CORP. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
ALBERT LABS INTL. CORP. Historical Marketcap From 2022 to 2026
Between 2022 and today, ALBERT LABS INTL. CORP.'s market cap moved from $2.00 Million to $ 434.98K, with a yearly change of -49.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €434.98K | 0.00% |
| 2025 | €434.98K | 0.00% |
| 2024 | €434.98K | +25.00% |
| 2023 | €347.99K | -82.61% |
| 2022 | €2.00 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ALBERT LABS INTL. CORP. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $372.07K USD |
| MoneyControl | $372.07K USD |
| MarketWatch | $372.07K USD |
| marketcap.company | $372.07K USD |
| Reuters | $372.07K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALBERT LABS INTL. CORP.
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.